

# HEALEY ALS Platform Trial

Weekly Q&A – May 12, 2022



## Healey Center


Sean M. Healey & AMG Center  
for ALS at Mass General



The AMG Foundation




# The HEALEY ALS Platform Trial is a Perpetual Adaptive Trial



# Study Results Timelines – Regimens A-D

**\*\*\* Note: COVID-19 might impact these estimates**



LPLV

(Last Participant Last Visit in the Randomized,  
Placebo Controlled Period)

Database Lock

Top Line Results

Study Reports

**Expected Database Lock: July-Oct 2022**

**Top Line Results: Aug-Nov 2022**

**Study Reports: Nov-Dec 2022**

# Enrollment Updates (as of May 12, 2022)

- **55** individuals have signed informed consent
- **34** individuals have been randomized within Regimen E


*Thank You*

**This breakthrough trial would not be possible without your participation**

Your **partnership** in research is what keeps us filled with passion, dedication, and the commitment to uncover new promising treatments for ALS

**Every research participant, whether on the active drug or placebo, plays a critical role in making the hope of finding a cure for ALS a reality**

# 33 Sites Currently Activated for Regimen E



(as of 5/12/22)

*Sites in blue participated in previous regimens. Sites in green (underlined to the side) are new additions to the Platform Trial!*

- Lehigh Valley Health Network
- Mass General Hospital
- University of Kansas
- University of Maryland
- California Pacific Medical Center
- Northwestern University
- Virginia Commonwealth University
- University of Nebraska
- Washington University
- Wake Forest University
- Hospital for Special Care
- Saint Alphonsus Regional
- University of Massachusetts
- Duke University
- Barrow Neurological Institute
- Georgetown University
- Texas Neurology
- Beth Israel Deaconess Medical Center
- SUNY Upstate
- Spectrum Health
- Henry Ford Hospital
- Essentia Health
- University of Southern California
- University of South Florida
- University of Colorado
- Providence Brain and Spine
- University of Minnesota
- Loma Linda University
- University of Iowa
- Swedish Medical Center
- Ohio State University
- University of Cincinnati
- Thomas Jefferson University

# Regimen E Site Activation

## Sites closest to activation:

- Mayo Rochester
- University of Pittsburgh
- University of CA, San Francisco
- Augusta University
- University of Washington
- Vanderbilt University

# Checking Site Status Online

## List of Participating Sites

*Sites marked "Recruiting" are currently enrolling participants in regimen E.*

*Sites marked "Active, Not recruiting" are active in the platform (for example, they are following participants in regimens A-D) but are not enrolling new participants at this time. Most active sites are expected to start enrolling in regimen E soon.*

Site	State	Enrollment Status	Contact Information
Lehigh Valley Health Network	PA	Recruiting	<a href="#">Andrew Orzel</a> (610-402-9543)
Penn State Hershey	PA	Active, Not recruiting	<a href="#">Heidi Runk</a>



<https://bit.ly/3g2NZr5>

# Patient Navigation

## Central resource for people living with ALS



Catherine Small

Phone: 833-425-8257 (HALT ALS)

E-mail: [healeyalsplatform@mgh.harvard.edu](mailto:healeyalsplatform@mgh.harvard.edu)

Weekly webinar  
registration:



<https://bit.ly/3r6Nd2L>

ALS Link sign-up:



<https://bit.ly/3o2Ds3m>

### Upcoming Guest Speakers:

**May 19th-** Nadia Sethi (Platform Trial Patient Advisory Committee Member)




Allison Bulat



# Send us webinar questions and ideas!


Travel around the  
US meeting  
Platform Trial Site  
Investigators



Guest speakers  
from partner  
foundations

Trehalose/SLS-005  
drug science and  
mechanism of action  
webinar with Seelos  
Therapeutics

<https://bit.ly/3L4hrdB>



Special Topics:  
Biomarkers, EAPs,  
Biostats, Science  
topics (epigenetics,  
epidemiology)